Skip to main content
Home Home

User account menu

  • Log in

Main navigation

  • Home
  • Topics
    • Antimicrobials
    • Asthma
    • Biological medicines
    • COVID-19 medicines
    • Cardiovascular disease
    • Equity
    • Focus medicines
    • Gout
    • Hepatitis C
    • Menopause
    • Type 2 diabetes
    • Youth mental health
  • Resources
    • All education/search
    • Brand changes
    • Clinical articles
    • HAH Bulletins
    • Podcasts
    • Recorded webinars
    • Reflect & audit activities
    • Resource hubs
    • Videos
  • EPiC dashboard
    • Go to EPiC
    • Join EPiC
    • EPiC FAQ
    • EPiC Demo
    • About EPiC
  • News
    • Events
    • That's Interesting
    • From The Team

Education

  1. Home
  2. Search

The hub for all your learning resources.

Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.

This item is over 2 years old; some content may no longer be current

Dulaglutide: the long-awaited new agent to treat type 2 diabetes

78 minutes to Watch

In this webinar, Dr Ryan Paul discusses the newly-funded type 2 diabetes medication dulaglutide, and provides advice on when and how to use it.

Contributor
Dr Ryan Paul (Ngāti Maru)
2 September 2021
  • Diabetes
  • Recorded webinars
This item is over 2 years old; some content may no longer be current

Can you say dulaglutide?

Dulaglutide is available from 1 September, but do you know how to pronounce it? Listen to our quick guide for help.

Contributor
He Ako Hiringa
30 August 2021
  • Videos
  • Diabetes
Image of a flowchart
This item is over 2 years old; some content may no longer be current

Initiating treatment with empagliflozin: Algorithms, notes and talking points

15 minutes to Delve

When clinically indicated, empagliflozin can be started in adult patients with type 2 diabetes using the steps shown in this resource (updated 24 Aug 2021).

Talking points, relevant for all patients starting empagliflozin, are provided along with two algorithms and accompanying prescribing notes. Which algorithm you follow will depend on your patient’s level of hypoglycaemia risk. 

Contributor
Brendan Duck, Ryan Paul (Ngāti Maru)
24 August 2021
  • Diabetes
  • Equity
  • Clinical article
This item is over 2 years old; some content may no longer be current

Heart failure therapy: from past to present

60 minutes to Watch

In this webinar, Dr Raewyn Fisher discusses the range of disease-modifying therapies that have improved heart failure outcomes, and provides reassurance around the funding changes to cilazapril.

Contributor
Dr Raewyn Fisher
24 August 2021
  • CVD
  • Recorded webinars
Bulletin #6
This item is over 2 years old; some content may no longer be current

Considering the new T2D agents

1 minute to Read

When initiating either empagliflozin or dulaglutide, the newly funded second-line type 2 diabetes agents,1 choice is based primarily on predominant comorbidities, clinical features and tolerability.

Administration route is an additional factor; dulaglutide is a once-weekly, subcutaneous injection and empagliflozin is a daily tablet. Patient factors are also important, and the contraindications and adverse effects profiles differ. 

Read the HAH Bulletin (updated July 2022) to find out more.

Contributor
He Ako Hiringa
17 August 2021
  • HAH Bulletins
  • Diabetes
Image of a molecular structure
This item is over 2 years old; some content may no longer be current

Introduction to biological medicines

4 minutes to Read + 15 minutes to Explore

Biological medicines are already used in Aotearoa New Zealand and with more being developed internationally, it’s important that health professionals feel comfortable prescribing, dispensing, and supporting patients to use them.

We’ve highlighted five key aspects of these medicines in an article and a series of short animated videos. After completing each section, you can take a short quiz to test your learning.

Contributor
He Ako Hiringa
11 August 2021
  • Biological medicines
  • Videos
  • Clinical article
Bulletin #5
This item is over 2 years old; some content may no longer be current

Cilazapril unplugged – what alternatives?

1 minute to Read

Prescribers wanting to block angiotensin II effects can consider the remaining funded ACE inhibitors or angiotensin II receptor blockers. ACE inhibitors and ARBs are similarly effective for hypertension, chronic renal disease and diabetic nephropathy, but ARBs are better tolerated. ACE inhibitors are preferred over ARBs first-line for heart failure and post myocardial infarction.

Read the HAH Bulletin to find out more.

Contributor
He Ako Hiringa
19 July 2021
  • HAH Bulletins
  • CVD
The 5 As - availability, accessibility, affordability and appropriateness
This item is over 2 years old; some content may no longer be current

The five drivers of medicine access equity

1 minute to Read

Pharmac has identified five key drivers of medicine access equity in New Zealand. Read on to learn about the drivers and how you can implement them in your place of work. 

13 July 2021
  • Equity
person leaping across a void
This item is over 2 years old; some content may no longer be current

Starting injectable medicine: How to prepare your T2D patients

7 minutes to Read

Dulaglutide, a once-weekly injectable medicine, will soon be available for second-line treatment of type 2 diabetes. As most people with type 2 diabetes will require an injectable therapy at some stage, it is important to build acceptability early in the patient journey.

Contributor
Louise Roche Farmer
29 June 2021
  • Diabetes
  • Clinical article
Bulletin #4
This item is over 2 years old; some content may no longer be current

Being culturally competent is not enough

1 minute to Read + 2 minutes to Delve

Cultural competence vs safety – related, but different

A culturally competent practitioner knows about the beliefs and behaviours of patients from different cultures, and has the skill to apply this knowledge to healthcare delivery.

Read the HAH Bulletin to find out more.

Contributor
He Ako Hiringa
21 June 2021
  • HAH Bulletins
  • Equity
HealthPathways
This item is over 2 years old; some content may no longer be current

Updated diabetes HealthPathways bravely paved with equity

6 minutes to Read

Careful writing and editing, and an equity lens, have been instrumental in updating the type 2 diabetes HealthPathways, helping to reduce unnecessary variation in treatment plans and outcomes.

 

Contributor
Lisa Dick
3 June 2021
  • Equity
Bulletin #3
This item is over 2 years old; some content may no longer be current

Improving medicine adherence to optimise outcomes

1 minute to Read + 2 minutes to Delve

Compliance, adherence, concordance – confused?

Whatever terminology is used, studies show that differences in health literacy, medicines access, attitudes to health and prescriber perceptions, may contribute to sub-optimal use of medicines and poor health outcomes.

Read the HAH Bulletin to find out about strategies to improve medicine access and supply.

Contributor
He Ako Hiringa
24 May 2021
  • HAH Bulletins
  • Equity

Pagination

  • « First First page
  • ‹ Previous Previous page
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next › Next page
  • Last » Last page
Home Home

Contact Us

Suite B, 2/20 Augustus Terrace, Parnell, Auckland 1052

PO Box 37590, Parnell, Auckland 1151

Support

09 488 4286

admin@akohiringa.co.nz

(9-5pm Mon-Fri)

Contact us

About us

Terms & Policies

  • Conditions for Use

Supported by

Pharmac

© Matui Limited. All rights reserved.

Developed by Matui Limited and brought to life by Communica.